As an analogue of GHRH, Mod GRF 1-29 (CJC-1295 without DAC) acts on receptors in the pituitary gland to stimulate the release of human growth hormone. Mod GRF 1-29 acts on receptors located in the anterior pituitary gland and signals the pituitary gland to increase the production of human growth hormone and cause the release of large amounts of human growth hormone in a pulsatile manner. The effects of Mod GRF 1-29 are very similar to what would be expected from long-term administration of synthetic HGH (see the Human Growth Hormone profile here), although the amount of time the released human growth hormone will remain in circulation is much shorter than with synthetic Human Growth Hormone. Therefore, multiple applications of Mod GRF 1-29 throughout the day are recommended to simulate the consistently elevated levels of human growth hormone. Mod GRF 1-29 (CJC-1295 without DAC) is commonly combined with a ghrelin mimetic (also known as a GHRP – Growth Hormone-Releasing Hexapeptide), such as GHRP-6, GHRP-2, Hexarelin, or Ipamorelin, in order to initiate and amplify a larger pulse of HGH from the pituitary gland compared to Mod GRF 1-29 used alone. The effects of a GHRH analog (such as Mod GRF 1-29) and a ghrelin mimetic (a GHRP such as GHRP-6 or Ipamorelin) are synergistic and amplify HGH release. For research purposes only.
As an analogue of GHRH, Mod GRF 1-29 (CJC-1295 without DAC) acts on receptors in the pituitary gland to stimulate the release of human growth hormone. Mod GRF 1-29 acts on receptors located in the anterior pituitary gland and signals the pituitary gland to increase the production of human growth hormone and cause the release of large amounts of human growth hormone in a pulsatile manner. The effects of Mod GRF 1-29 are very similar to what would be expected from long-term administration of synthetic HGH (see the Human Growth Hormone profile here), although the amount of time the released human growth hormone will remain in circulation is much shorter than with synthetic Human Growth Hormone. Therefore, multiple applications of Mod GRF 1-29 throughout the day are recommended to simulate the consistently elevated levels of human growth hormone. Mod GRF 1-29 (CJC-1295 without DAC) is commonly combined with a ghrelin mimetic (also known as a GHRP – Growth Hormone-Releasing Hexapeptide), such as GHRP-6, GHRP-2, Hexarelin, or Ipamorelin, in order to initiate and amplify a larger pulse of HGH from the pituitary gland compared to Mod GRF 1-29 used alone. The effects of a GHRH analog (such as Mod GRF 1-29) and a ghrelin mimetic (a GHRP such as GHRP-6 or Ipamorelin) are synergistic and amplify HGH release. For research purposes only.